University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
NCT Number: NCT06456242
Many hospitals and outpatient clinics often refer people who smoke to quitlines and provide prescriptions for smoking cessation medications, but patients rarely fully engage in counseling or use their cessation medications. This is a single-arm, open-label pilot study to provide feasibility metrics for a text-based contingency management (CM) intervention to increase engagement in smoking cessation treatment. All participants (N=20) will be referred to a state quitline and will receive a prescription for medication plus 12 weeks of a text-based CM intervention to increase engagement in quitline calls and varenicline utilization. The engagement of participants in quitline counseling will be tracked for 6 weeks and medication utilization for 12 weeks post-enrollment. The investigators will use mixed-methods to collect implementation and acceptability data to inform changes to the text-based contingency management (CM) intervention.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Kansas City, Kansas, 66103, United States
Novel approaches are needed to engage people who smoke in treatment in a way that increases their odds of quitting. Contingency management (CM) interventions provide financial incentives to participants contingent on objective evidence of behavior change and are effective in enhancing medication adherence and treatment engagement for numerous health conditions, including tobacco dependence treatment. Critical gaps, however, remain in our knowledge regarding how best to deploy CM.
The goal of this study is to evaluate the acceptability and feasibility of combined CM for engaging patients in smoking cessation treatment. Participants (N=20) will receive "CounsCM" for engaging in five quitline calls and "MedCM" for utilizing varenicline over twelve weeks. CM payments will be automated and dispensed on a daily basis using a reloadable debit card. The investigators will use surveys and structured interviews to understand strengths, weaknesses, and areas for improvement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
Time frame: Week 6
Completion of the five quitline calls over 6 weeks of treatment according to Kansas quitline reports
Time frame: Week 12
Varenicline intake over 12 weeks of treatment according to the smart pill dispenser counting
Time frame: Week 3
Adherence biochemically verified using saliva samples, 1.0 ng/ml as the cutoff to distinguish between participants adherent and adherent
Time frame: Week 3
Self-reported use of varenicline from a timeline followback questionnaire assessing varenicline pills taken in each of the past 3 days
Time frame: Week 12
Biochemically confirmed 7-day point prevalence abstinence using the anabasine criteria cutoff of ≤ 2 ng/ml
Time frame: Week 12
Past 7 days self-reported smoking abstinence
University of Kansas Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05130788
Behavior, Health Behavior
New York, United States
View Trial DetailsNCT06663020
Behavior, Bronchial Neoplasms
Samsun, Turkey (Türkiye)
View Trial DetailsNCT04881630
Behavior, Health Behavior
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04620915
Behavior, Cancer
Eugene, Oregon, United States
View Trial Details